Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Grant | Alive

Total Raised


Last Raised

$330K | 2 yrs ago

About Vivasc Therapeutics

Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. The company utilizes Cardiac Targeting Peptide (CTP) platform technology to deliver various cargo exclusively to cardiomyocytes in a non-invasive manner.

Vivasc Therapeutics Headquarters Location

Pittsburgh, Pennsylvania,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vivasc Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vivasc Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Vivasc Therapeutics News

Ventricular Tachycardia (V-tach or VT) Drug Pipeline Insight Report 2022 Featuring Espero BioPharma, CTP amio Vivasc Therapeutics, Aladorian - ARMGO Pharma, & RyR2 Research Program -

Sep 12, 2022

This Ventricular Tachycardia (V-tach or VT) - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Ventricular Tachycardia (V-tach or VT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. A detailed picture of the Ventricular Tachycardia (V-tach or VT) pipeline landscape is provided which includes the disease overview and Ventricular Tachycardia (V-tach or VT) treatment guidelines. The assessment part of the report embraces, in depth Ventricular Tachycardia (V-tach or VT) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ventricular Tachycardia (V-tach or VT) collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Ventricular Tachycardia (V-tach or VT) R&D. The therapies under development are focused on novel approaches to treat/improve Ventricular Tachycardia (V-tach or VT). This segment of the Ventricular Tachycardia (V-tach or VT) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Ventricular Tachycardia (V-tach or VT) Drugs ARM210: ARMGO Pharma ARM210 is a small molecule that binds to leaky RyR channels and repairs the leak, as demonstrated in vitro in muscle biopsies from RYR1-RM patients.ARM210 for the treatment of CPVT, a rare form of ventricular tachycardia and sudden death caused by mutations in the ryanodine receptor 2 (RyR2) which controls Ca2+ homeostasis in cells. Ventricular Tachycardia (V-tach or VT): Therapeutic Assessment This segment of the report provides insights about the Ventricular Tachycardia (V-tach or VT) drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Ventricular Tachycardia (V-tach or VT) There are approx. 5+ key companies which are developing the therapies for Ventricular Tachycardia (V-tach or VT). The companies which have their Ventricular Tachycardia (V-tach or VT) drug candidates in the most advanced stage, i.e. Phase II include ARMGO Pharma. Phases Late stage products (Phase III) Mid-stage products (Phase II)

  • Where is Vivasc Therapeutics's headquarters?

    Vivasc Therapeutics's headquarters is located at Pittsburgh.

  • What is Vivasc Therapeutics's latest funding round?

    Vivasc Therapeutics's latest funding round is Grant.

  • How much did Vivasc Therapeutics raise?

    Vivasc Therapeutics raised a total of $330K.

  • Who are the investors of Vivasc Therapeutics?

    Investors of Vivasc Therapeutics include National Heart Lung and Blood Institute.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.